share_log

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $57 Price Target

Moomoo 24/7 ·  Apr 23 12:32

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment